- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07800897
A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants
A Phase 1, Open-label, Randomized, Pharmacokinetic Study to Assess the Drug Interactions and Food Effect of Navlimetostat (BMS-986504) in Healthy Female Participants
The purpose of this study is to assess the food effect and drug interactions on drug levels of Navlimetostat in health adult female participants
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: First line of the email MUST contain NCT # and Site #.
Sauvegarde des contacts de l'étude
- Nom: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Numéro de téléphone: 855-907-3286
- E-mail: Clinical.Trials@bms.com
Lieux d'étude
-
-
Quebec
-
Québec, Quebec, Canada, G1P 0A2
- Recrutement
- Syneos Health Clinique; Inc.
-
Contact:
- Lidia Facchinelli, Site 0001
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
- Participants must be healthy adult female (as assigned at birth) individuals not of childbearing potential (INOCBP) who have no clinically significant findings on medical history, physical examination (PE), vital signs (VS), 12-lead electrocardiograms (ECGs), or clinical laboratory determinations, as assessed by the investigator.
- Participants must have a BMI of 18.0 to 35.0 kg/m2, inclusive.
Exclusion Criteria
- Participants must not have any significant acute or chronic medical illness (in the assessment of the investigator).
- Participants must not have a history of prolonged bleeding or excessive bruising.
- Participants must not have any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Partie 2
|
Specified dose on specified days
Autres noms:
Specified dose on specified days |
|
Expérimental: Partie 3
|
Specified dose on specified days
Autres noms:
|
|
Expérimental: Partie 1A
|
Specified dose on specified days
Autres noms:
Specified dose on specified days |
|
Expérimental: Partie 1B
|
Specified dose on specified days
Autres noms:
Specified dose on specified days |
|
Expérimental: Part 4
|
Specified dose on specified days
Autres noms:
Specified dose on specified days |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Drug-related AEs
Délai: Up to approximately 6 weeks
|
Up to approximately 6 weeks
|
|
|
Maximum observed concentration (Cmax) of Navlimetostat
Délai: Up to approximately 3 weeks
|
Part 1A, Part 1B, Part 3, Part 4 |
Up to approximately 3 weeks
|
|
Area under the concentration-time curve from time zero to 192 hours (AUC(0-192)) of Navlimetostat
Délai: Up to approximately 3 weeks
|
Part 1A |
Up to approximately 3 weeks
|
|
(AUC(INF)) of Navlimetostat with the coadministration of itraconazole
Délai: Up to approximately 3 weeks
|
Part 1A |
Up to approximately 3 weeks
|
|
AUC(INF) of Navlimetostat without the coadministration of itraconazole
Délai: Up to approximately 3 weeks
|
Part 1A |
Up to approximately 3 weeks
|
|
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Navlimetostat
Délai: Up to approximately 3 weeks
|
Part 1B, Part 3, Part 4 |
Up to approximately 3 weeks
|
|
AUC(INF) of Navlimetostat with the coadministration of Rifampin
Délai: Up to approximately 3 weeks
|
Part 1B |
Up to approximately 3 weeks
|
|
AUC(INF) of Navlimetostat without the coadministration of Rifampin
Délai: Up to approximately 3 weeks
|
Part 1B |
Up to approximately 3 weeks
|
|
Cmax of Midazolam
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
AUC(0-T) of Midazolam
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
AUC(INF) of Midazolam with the coadministration of Navlimetostat
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
AUC(INF) of Midazolam without the coadministration of Navlimetostat
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
AUC(INF) of Navlimetostat with a high fat meal
Délai: Up to approximately 3 weeks
|
Part 3 |
Up to approximately 3 weeks
|
|
AUC(INF) of Navlimetostat without a high fat meal
Délai: Up to approximately 3 weeks
|
Part 3 |
Up to approximately 3 weeks
|
|
AUC(INF) of Navlimetostat with the coadministration of Pantoprazole
Délai: Up to approximately 3 weeks
|
Part 4 |
Up to approximately 3 weeks
|
|
AUC(INF) of Navlimetostat without the coadministration of Pantoprazole
Délai: Up to approximately 3 weeks
|
Part 4 |
Up to approximately 3 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Adverse events (AEs)
Délai: Up to approximately 6 weeks
|
Up to approximately 6 weeks
|
|
|
Serious adverse events (SAEs)
Délai: Up to approximately 6 weeks
|
Up to approximately 6 weeks
|
|
|
AEs leading to discontinuation of study or study intervention
Délai: Up to approximately 6 weeks
|
Up to approximately 6 weeks
|
|
|
Number of participants with clinically significant changes in physical examination (PE)
Délai: Up to approximately 6 weeks
|
Up to approximately 6 weeks
|
|
|
Number of participants with clinically significant changes in vital signs (VS)
Délai: Up to approximately 6 weeks
|
Up to approximately 6 weeks
|
|
|
Number of participants with clinically significant changes in 12-lead electrocardiograms (ECGs)
Délai: Up to approximately 6 weeks
|
Up to approximately 6 weeks
|
|
|
Number of participants with clinically significant changes in clinical laboratory test results
Délai: Up to approximately 6 weeks
|
Up to approximately 6 weeks
|
|
|
Cmax of Navlimetostat Metabolite
Délai: Up to approximately 3 weeks
|
Up to approximately 3 weeks
|
|
|
AUC(0-T) of Navlimetostat Metabolite
Délai: Up to approximately 3 weeks
|
Up to approximately 3 weeks
|
|
|
AUC(INF) of Navlimetostat Metabolite
Délai: Up to approximately 3 weeks
|
Up to approximately 3 weeks
|
|
|
Tmax of Navlimetostat Metabolite
Délai: Up to approximately 3 weeks
|
Up to approximately 3 weeks
|
|
|
T-HALF of Navlimetostat Metabolite
Délai: Up to approximately 3 weeks
|
Up to approximately 3 weeks
|
|
|
Mean ratio (MR)_Cmax of Navlimetostat Metabolite
Délai: Up to approximately 3 weeks
|
Up to approximately 3 weeks
|
|
|
MR_AUC(0-T) of Navlimetostat Metabolite
Délai: Up to approximately 3 weeks
|
Up to approximately 3 weeks
|
|
|
MR_AUC(INF) of Navlimetostat Metabolite
Délai: Up to approximately 3 weeks
|
Up to approximately 3 weeks
|
|
|
AUC(0-T) of Navlimetostat
Délai: Up to approximately 3 weeks
|
Part 1A |
Up to approximately 3 weeks
|
|
Time of maximum observed concentration (Tmax) of Navlimetostat
Délai: Up to approximately 3 weeks
|
Part 1A, Part 1B, Part 3, Part 4 |
Up to approximately 3 weeks
|
|
Half-life (T-HALF) of Navlimetostat
Délai: Up to approximately 3 weeks
|
Part 1A, Part 1B, Part 3, Part 4 |
Up to approximately 3 weeks
|
|
Apparent total body clearance (CLT/F) of Navlimetostat
Délai: Up to approximately 3 weeks
|
Part 1A, Part 1B, Part 3, Part 4 |
Up to approximately 3 weeks
|
|
Apparent volume of distribution at terminal phase (Vz/F) of Navlimetostat
Délai: Up to approximately 3 weeks
|
Part 1A, Part 1B, Part 3, Part 4 |
Up to approximately 3 weeks
|
|
Tmax of Midazolam
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
T-HALF of Midazolam
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
CLT/F of Midazolam
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
Vz/F of Midazolam
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
AUC(0-192) of Navlimetostat Metabolite
Délai: Up to approximately 3 weeks
|
Part 1A |
Up to approximately 3 weeks
|
|
AUC(0-24) of Navlimetostat Metabolite
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
MR_AUC(0-192) of Navlimetostat Metabolite
Délai: Up to approximately 3 weeks
|
Part 1A |
Up to approximately 3 weeks
|
|
MR_AUC(0-24) of Navlimetostat Metabolite
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
Cmax of Rifampin
Délai: Up to approximately 3 weeks
|
Part 1A and Part 1B |
Up to approximately 3 weeks
|
|
Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of Rifampin
Délai: Up to approximately 3 weeks
|
Part 1A and Part 1B |
Up to approximately 3 weeks
|
|
Trough observed concentration (Ctrough) of Rifampin
Délai: Up to approximately 3 weeks
|
Part 1A and Part 1B |
Up to approximately 3 weeks
|
|
Tmax of Rifampin
Délai: Up to approximately 3 weeks
|
Part 1A and Part 1B |
Up to approximately 3 weeks
|
|
Cmax of 1-hydroxymidazolam
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
AUC(0-T) of 1-hydroxymidazolam
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
AUC(INF) of 1-hydroxymidazolam
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
Tmax of 1-hydroxymidazolam
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
T-HALF of 1-hydroxymidazolam
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
MR_Cmax of 1-hydroxymidazolam
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
MR_AUC(0-T) of 1-hydroxymidazolam
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
MR_AUC(INF) of 1-hydroxymidazolam with the coadministration of Navlimetostat
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
|
MR_AUC(INF) of 1-hydroxymidazolam without the coadministration of Navlimetostat
Délai: Up to approximately 3 weeks
|
Part 2 |
Up to approximately 3 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- 2-pyridinylméthylsulfinylbenzimidazoles
- Sulfoxydes
- Composés de soufre
- Produits chimiques organiques
- Pyridines
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Benzimidazoles
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Azoles
- Composés polycycliques
- Benzazépines
- Composés hétérocycliques, 4 anneaux ou plus
- Rifamycines
- Lactams, macrocyclique
- Composés macrocycliques
- Benzodiazépines
- Triazoles
- Pipérazines
- Pantoprazole
- Midazolam
- Rifampicine
- Itraconazole
Autres numéros d'identification d'étude
- CA240-0050
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Délai de partage IPD
See Plan Description
Critères d'accès au partage IPD
See Plan Description
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .